Buparlisib Completed Phase 2 Trials for Advanced Endometrial Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01289041BKM120 as Second-line Therapy for Advanced Endometrial Cancer